药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02268 药明合联

已收盘 05-28 16:08:31

52.800

-4.500

-7.85%

最高57.300	最低52.600	成交量661.02万
今开57.300	昨收57.300	日振幅8.20%
总市值665.81亿	流通市值665.81亿	总股本12.61亿
成交额3.56亿	换手率0.52%	流通股本12.61亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02268","market":"HK","secType":"STK","nameCN":"药明合联","latestPrice":52.8,"timestamp":1779955711004,"preClose":57.3,"halted":0,"volume":6610239,"delay":0,"changeRate":-0.07853403141361257,"floatShares":1261000000,"shares":1261000000,"eps":1.2952983075500677,"marketStatus":"已收盘","change":-4.5,"latestTime":"05-28 16:08:31","open":57.3,"high":57.3,"low":52.6,"amount":356057582,"amplitude":0.082024,"askPrice":52.8,"askSize":123500,"bidPrice":52.7,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":1.2933750191494033,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780018200000},"marketStatusCode":5,"adr":0,"listingDate":1700150400000,"exchange":"SEHK","adjPreClose":57.3,"openAndCloseTimeList":[[1779931800000,1779940800000],[1779944400000,1779955200000]],"volumeRatio":1.204377,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02268","defaultTab":"news","newsList":[{"id":"2638663070","title":"港股收评：恒指跌1.27%险守25000点 科指跌0.39% 科网股低迷 黄金股普跌 智谱逆势涨超13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638663070","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638663070?lang=zh_cn&edition=full","pubTime":"2026-05-28 16:08","pubTimestamp":1779955680,"startTime":"0","endTime":"0","summary":"　　5月28日消息，港股三大指数集体下跌。截至收盘，恒生指数跌1.27%，报25006.16，恒生科技指数跌0.39%，国企指数跌1.17%。盘面上，科网股跌多涨少，美团跌超5%，阿里巴巴、腾讯、哔哩哔哩、百度跌超2%，联想涨超3%；黄金股普跌，中国黄金国际跌超6%；创新药概念股持续走弱，药明合联跌超7%；AI应用股部分上涨，智谱涨超13%。　　AI应用股部分上涨，智谱涨超13%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-05-28/doc-inhzmtwq8653089.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SG9999014674.SGD","07300","HSI","03088","BK1592","03067","HHImain","02513","02099","09115","SG9999003461.SGD","02268","BK1117","03115","SG9999001093.SGD","07226","03032","JINFF","02837","03037","02833","07200","BK1544","09088","02800","09067","BK1198","07500","BK1141","03417","03423","HSTECH","07552","03419","513600","MCHmain","83115","LU2488822045.USD","03033","82800"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187958849","title":"异动解读｜药明合联盘中下跌3.14%，密集回购未能扭转板块持续抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1187958849","media":"行情直击","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187958849?lang=zh_cn&edition=full","pubTime":"2026-05-28 09:46","pubTimestamp":1779932784,"startTime":"0","endTime":"0","summary":"5月28日，药明合联盘中下跌3.14%，报55.4港元/股，成交额2810.37万港元，连续多个交易日走弱。消息面上，公司此前公告拟动用最多1亿美元内部资金在公开市场回购股份，母公司药明生物亦宣布不超过4亿美元回购计划，合计回购规模达5亿美元。然而密集回购仍未能有效提振市场信心，药明系个股整体承压，药明康德跌3.52%、药明生物跌2.73%。国泰海通维持公司\"增持\"评级，目标价84.38港元，看好ADC赛道增长前景。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110755377","title":"异动解读｜药明合联盘中下跌3.04%，回购利好未能抵消板块持续抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1110755377","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110755377?lang=zh_cn&edition=full","pubTime":"2026-05-27 10:58","pubTimestamp":1779850685,"startTime":"0","endTime":"0","summary":"5月27日，药明合联盘中下跌3.04%，报55.75港元/股，成交额8616.81万港元。消息面上，公司此前公告拟动用最多1亿美元内部资金在公开市场回购股份，母公司药明生物亦于5月26日宣布不超过4亿美元的回购计划，合计回购规模达5亿美元。然而密集回购未能有效提振股价，板块整体承压明显。生命科学工具和服务行业中，药明生物跌1.22%、药明康德跌1.55%、晶泰控股跌3.11%。国泰海通维持公司\"增持\"评级，目标价84.38港元，看好ADC赛道增长前景。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638001595","title":"【券商聚焦】国泰海通维持药明合联(02268)“增持”评级 指其回购彰显长期信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2638001595","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638001595?lang=zh_cn&edition=full","pubTime":"2026-05-26 14:41","pubTimestamp":1779777692,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国泰海通证券发布研报指，药明合联 拟使用最高1亿美元内部资金开展股份回购，彰显长期发展信心。公司现金储备充裕，为资本开支提供坚实基础。国泰海通看好ADC等新模态药物带动下对CDMO需求的提升及公司业绩的持续兑现，维持“增持”评级，目标价84.38港元。2025年，在金额超过10亿美元的ADC并购交易中，50%的被收购方是药明合联客户。未完成订单约14.89亿美元，同比增长50.3%；新签合同价值13.3亿美元，同比增长41%。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1982186","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02611","02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153962782","title":"异动解读｜药明合联盘中下跌3.14%，报56.05港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153962782","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153962782?lang=zh_cn&edition=full","pubTime":"2026-05-26 10:09","pubTimestamp":1779761383,"startTime":"0","endTime":"0","summary":"5月26日，药明合联盘中下跌3.14%，报56.05港元/股，成交额6748.74万港元。药明合联所在的生命科学工具和服务行业中，个股表现分化，其中药明生物涨3.73%，金斯瑞生物科技涨0.08%，药明康德跌2.0%，晶泰控股跌2.39%，英矽智能跌3.77%。药明合联生物技术有限公司是一家主要从事提供抗体偶联药物（ADC）及其他生物偶联药物的全面合同研究、开发及制造组织（CRDMO）服务的投资控股公司，业务覆盖国内市场、北美、欧洲和世界其他地区。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175372022","title":"异动解读｜药明合联盘中下跌3.03%，报55.95港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1175372022","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175372022?lang=zh_cn&edition=full","pubTime":"2026-05-21 15:36","pubTimestamp":1779348968,"startTime":"0","endTime":"0","summary":"5月21日，药明合联盘中下跌3.03%，报55.95港元/股，成交额1.48亿港元。药明合联所在的生命科学工具和服务行业中，个股表现分化，其中昭衍新药涨6.06%，药明康德涨1.62%，晶泰控股涨0.76%，药明生物跌1.03%，英矽智能跌4.78%。药明合联是一家主要从事抗体偶联药物（ADC）及其他生物偶联药物的全面合同研究、开发及制造组织（CRDMO）服务的投资控股公司，业务覆盖国内市场、北美、欧洲和世界其他地区。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636589432","title":"港股异动 | 药明合联(02268)再涨超6% 拟斥最多1亿美元回购股份 公司盈利可见性增强","url":"https://stock-news.laohu8.com/highlight/detail?id=2636589432","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636589432?lang=zh_cn&edition=full","pubTime":"2026-05-20 10:40","pubTimestamp":1779244809,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，药明合联再涨超6%，截至发稿，涨6.35%，报58.65港元，成交额1.69亿港元。消息面上，药明合联日前公布，公司已议决动用最多1亿美元的内部资金，委托专业受托人在公开市场购买公司股份。值得一提的是，截至2025年末，药明合联未完成订单总量为14.89亿美元，同比增长50.3%，充沛的未完成订单为未来业绩提供保障。该行认为这增强公司的盈利可见性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443793.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LU2488822045.USD","SG9999014674.SGD","02268","BK1141","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103975812","title":"异动解读｜药明合联盘中上涨3.17%，公司拟斥资最多1亿美元回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1103975812","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103975812?lang=zh_cn&edition=full","pubTime":"2026-05-20 10:06","pubTimestamp":1779242811,"startTime":"0","endTime":"0","summary":"5月20日，药明合联盘中上涨3.17%，报56.9港元/股，成交额5503.44万港元。消息面上，药明合联于5月18日公告，公司已议决动用最多1亿美元内部资金，委任专业受托人按当时市价在公开市场购买公司股份。公司明确表示，当前股份交易价格并未反映其内在价值或实际业务前景，认为此时进行回购系良机。董事会认为集团目前财务资源充裕，能以内部资源实施回购的同时维持稳固财务状况。此外，生物医药板块近期整体表现偏强，叠加回购利好持续发酵，推动股价延续上行。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636885146","title":"生物医药板块盘初普涨 药明合联(02268)涨5.24%、百济神州(06160)涨2.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636885146","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636885146?lang=zh_cn&edition=full","pubTime":"2026-05-19 09:46","pubTimestamp":1779155169,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股生物医药板块盘初普涨，截至发稿，药明合联 涨5.24%，科伦博泰生物涨4.01%，百济神州涨2.17%，诺诚健华涨2.00%，药明生物涨1.58%，康诺亚-B涨1.35%，金斯瑞生物科技涨1.12%。消息面上，中邮证券研究表示，26年有望迎来BD和重点项目数据读出的双重催化，国产创新药全球性竞争力提升逻辑不断强化。建议关注确定性高、BD预期扰动相对小的标的。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981657","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320764599.SGD","BK1576","LU0823426308.USD","02268","LU1242518931.SGD","06990","SG9999014674.SGD","LU0708995583.HKD","LU0052750758.USD","LU0348825331.USD","06160","LU0417516902.SGD","BK1574","LU0307460666.USD","XBI","ONC","LU1251922891.USD","01548","LU0181495838.USD","LU3063872942.SGD","02269","BK1161","IE00B0JY6N72.USD","LU1303224171.USD","09969","688235","BK1583","BK4588","LU0417516738.SGD","LU0516422366.SGD","161726","LU0516422440.USD","LU0359202008.SGD","BK1588","HK0000306701.USD","LU0359201612.USD","LU1770034418.SGD","HK0000320264.USD","BK1589","LU1688375341.USD","LU0588546209.SGD","LU1719994722.HKD","BK4581","BK1141","LU0043850808.USD","LU0039217434.USD","LU0456846285.SGD","399441","SG9999002562.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636742670","title":"药明合联拟动用最多1亿美元的内部资金购买股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2636742670","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636742670?lang=zh_cn&edition=full","pubTime":"2026-05-18 22:40","pubTimestamp":1779115256,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明合联(02268)公布，公司已议决其动用最多1亿美元的内部资金，以供公司不时为公司股份计划委任的专业受托人按当时市价在公开市场上购买公司股份。公司认为，股份目前的交易价格并未反映其内在价值或公司的实际业务前景，此乃公司进行建议股份购买的良机。董事会认为，集团目前的财务资源能使其以内部资源实施建议股份购买，同时为集团营运的持续增长维持稳固的财务状况。","market":"sh","thumbnail":"https://static.tigerbbs.com/9194f9fb43dce1485f0258ebbb901e84","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/9194f9fb43dce1485f0258ebbb901e84"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443163.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明合联拟动用最多1亿美元的内部资金购买股份","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999014674.SGD","02268","BK1141","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636048086","title":"创新药概念走软 药明合联(02268)领跌5.57% 机构成仍看好以创新为主医药科技主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2636048086","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636048086?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:09","pubTimestamp":1779070152,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念整体走软，截至发稿，药明合联 跌5.57%，亚盛医药-B跌5.50%，四环医药跌4.55%，康方生物跌4.49%，歌礼制药-B跌4.36%，同源康医药-B跌4.31%，康诺亚-B跌4.24%，荣昌生物跌4.14%。展望2026年，该机构继续看好以创新为主的医药科技主线，重点关注创新药、脑机接口、AI医疗、手术机器人等，同时建议布局2026年行业有望迎来反转的老龄化及院外消费，关注估值较低的麻药、血制品、中药等。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981521","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348735423.USD","IE00B543WZ88.USD","09926","BK1587","LU2488822045.USD","BK1191","LU0348827113.USD","LU0417516902.SGD","LU0348784397.USD","02268","159992","LU2476274720.SGD","LU0634319403.HKD","01672","00460","IE00BPRC5H50.USD","159938","BK1141","BK1593","02410","LU0417516571.SGD","LU0561508036.HKD","LU1961090484.USD","09939","BK1515","LU0348766576.USD","BK1574","BK1600","09995","06978","LU0348767384.USD","06855","LU1794554557.SGD","LU1969619763.USD","LU2399975544.HKD","BK1161","LU2476274308.USD","LU0348825331.USD","LU0348783233.USD","LU2778985437.USD","LU2328871848.SGD","BK1583","LU0540923850.HKD","SG9999014674.SGD","LU0417516738.SGD","IE00B5MMRT66.SGD","LU1720050803.USD","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633687104","title":"【券商聚焦】中国银河：医药行业进入复苏周期 CXO板块景气度较高","url":"https://stock-news.laohu8.com/highlight/detail?id=2633687104","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633687104?lang=zh_cn&edition=full","pubTime":"2026-05-08 09:00","pubTimestamp":1778202049,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国银河证券表示，2025年医药行业上市公司营业收入增长0.4%，归母净利润增长3.9%，扣非净利润下降4.1%，2026年一季度营业收入增长1.1%，归母净利润下降3.2%，扣非净利润增长2.0%。2025全年医药行业收入端小幅微增，主要系医保控费趋严，仿制药、耗材等集采常态化开展导致行业承压。2026年一季度创新药产业链高景气度延续，收入增幅扩大、非经常性损益占比下降，行业整体经营盈利能力提升，进入复苏上行周期。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980878","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0588546209.SGD","06881","BK1161","BK1585","HK0000165453.HKD","LU0348767384.USD","LU2328871848.SGD","LU2476274720.SGD","03933","LU0417516902.SGD","LU2778985437.USD","02367","BK1583","LU0348766576.USD","02228","BK1593","BK1141","CXO","LU0640798160.USD","LU1719994722.HKD","BK1500","BK1588","02196","LU0348783233.USD","LU0561508036.HKD","06821","LU1303224171.USD","LU0307460666.USD","BK0276","01789","LU1251922891.USD","LU1794554557.SGD","02268","01530","BK1207","IE00BPRC5H50.USD","LU1961090484.USD","09688","LU0348735423.USD","06160","01099","LU0417516571.SGD","LU0417516738.SGD","LU0634319403.HKD","BK1197","09926","BK0188","601881","LU2488822045.USD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185863319","title":"药明合联4月股份变动月报：增发177万余股","url":"https://stock-news.laohu8.com/highlight/detail?id=1185863319","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185863319?lang=zh_cn&edition=full","pubTime":"2026-05-06 17:56","pubTimestamp":1778061364,"startTime":"0","endTime":"0","summary":"药明合联生物技术有限公司于2026年5月6日发布了截至2026年4月30日的证券变动月报。公告显示，公司4月末法定股本维持在100亿股，面值0.00005美元，总注册股本约50万美元，与上月底持平。公司截至4月30日的已发行普通股数从上月底的1,258,835,897股增至1,260,609,335股，期间增发1,773,438股。根据公告，新增发行股份主要来自若干购股权行使。其中包括2021年和2023年多期首次公开发售前购股权计划，共计行使股份1,773,438股，对应行权所得资金合计人民币4,449,564.86元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631562350","title":"港股异动 | 东曜药业-B(01875)盘中涨超9% 药明合联CEO李锦才接任执行董事、董事会主席","url":"https://stock-news.laohu8.com/highlight/detail?id=2631562350","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631562350?lang=zh_cn&edition=full","pubTime":"2026-04-29 15:34","pubTimestamp":1777448085,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东曜药业-B盘中涨超9%，截至发稿，涨6.77%，报4.89港元，成交额1957.1万港元。消息面上，东曜药业公布多位管理层变动。其中，李锦才则获委任为执行董事、董事会主席、提名委员会主席、战略及ESG委员会主席以及薪酬委员会成员，自4月29日起生效。公开资料显示，今年3月，药明合联完成对东曜药业的现金要约收购。国投证券国际指出，东曜药业实现华丽转型，由传统制药企业摇身成为CDMO赛道的领军企业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436092.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1574","BK1161","02268","LU2488822045.USD","VXUS","BK1141","01875","SG9999014674.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188665719","title":"异动解读 | 药明合联盘中大涨5.09%，年度业绩高增叠加板块联动走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1188665719","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188665719?lang=zh_cn&edition=full","pubTime":"2026-04-28 09:43","pubTimestamp":1777340584,"startTime":"0","endTime":"0","summary":"药明合联今日盘中大涨5.09%，引起了市场的广泛关注。消息面上，公司此前披露的年度业绩表现强劲，成为推动股价上涨的主要动力。数据显示，公司实现收入59.44亿元人民币，同比增长46.6%，这主要得益于ADC等生物偶联CRDMO服务需求的拉动。同时，公司毛利率由30.6%显著提升至36.0%，年内溢利同比增长38.4%至14.80亿元人民币，显示出盈利能力的显著改善。此外，今日生命科学工具和服务板块整体表现强势，板块联动效应明显。同板块的药明康德、康龙化成、昭衍新药及药明生物等公司股价均有不同程度上涨，市场情绪积极，进一步带动了药明合联的股价表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199728468","title":"药明合联2025年度收入同比增长46.6%，业务与产能加速扩张","url":"https://stock-news.laohu8.com/highlight/detail?id=1199728468","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199728468?lang=zh_cn&edition=full","pubTime":"2026-04-24 16:52","pubTimestamp":1777020773,"startTime":"0","endTime":"0","summary":"药明合联生物技术有限公司在截至2025年12月31日止年度实现收入59.44亿元人民币，较2024年的40.52亿元人民币增长46.6%，主要来自ADC等生物偶联领域的CRDMO服务需求拉动。公司毛利同比上升72.5%至21.39亿元人民币，毛利率由上一年的30.6%提升至36.0%。年内溢利达到14.80亿元人民币，同比增长38.4%；调整后净利润为15.59亿元人民币，同比增长32.7%。公司于2025年无重大违规事项披露，董事会认为内部控制在报告期内保持有效。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明合联2025年度收入同比增长46.6%，业务与产能加速扩张","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628719049","title":"招银国际：医疗板块风险偏好有温和的修复 推荐翰森制药(03692)等6股","url":"https://stock-news.laohu8.com/highlight/detail?id=2628719049","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628719049?lang=zh_cn&edition=full","pubTime":"2026-04-20 11:36","pubTimestamp":1776656176,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，MSCI中国医疗指数2026年初至今累计上涨12.3%，跑赢MSCI中国指数13.6%。近期在中国政府工作报告将生物医学列为新兴支柱产业的政策催化下，板块风险偏好有温和的修复。同时，AI制药技术突破与中国创新药出海 BD 的爆发形成双重共振，该行预期产业基本面加速向好。招商国际给予该6只股份“买入”的投资评级，目标价分别为46.41港元、113.86港元、34.87港元、10.34港元、82港元及35.46美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0502904849.HKD","BK1583","LU0455707207.USD","01530","159891","LU2097828805.USD","LU2097828714.EUR","BK1593","BK1161","LU2328871848.SGD","01801","BK1141","LU2488822045.USD","HK0000165453.HKD","LU2242644610.SGD","LU2097828474.EUR","BK1574","LU2097828557.USD","BK1589","03692","BK1191","SG9999014674.SGD","02268","01167","LU1969619763.USD","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625944762","title":"药明合联(02268.HK)授出485.45万股受限制股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2625944762","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625944762?lang=zh_cn&edition=full","pubTime":"2026-04-08 21:17","pubTimestamp":1775654222,"startTime":"0","endTime":"0","summary":"格隆汇4月8日丨药明合联(02268.HK)宣布，于2026年4月8日，根据2024年股份计划，其已批准向425名承授人(其中三名为董事，而余下422名承授人为集团雇员)授出485.45万股受限制股份，惟须经选定参与者接纳。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260408/32132000.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["SG9999014674.SGD","02268","LU2488822045.USD","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625944552","title":"药明合联(02268)因期权获行使而发行合共120.3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2625944552","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625944552?lang=zh_cn&edition=full","pubTime":"2026-04-08 21:07","pubTimestamp":1775653623,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明合联(02268)发布公告，于2026年4月8日，根据首次公开发售前购股权计划为行使期权而发行合共120.3万股普通股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999014674.SGD","02268","BK1141","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104892603","title":"药明合联多次行使期权合计发行约150.74万股，约占已发行股本0.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=1104892603","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104892603?lang=zh_cn&edition=full","pubTime":"2026-04-08 21:05","pubTimestamp":1775653552,"startTime":"0","endTime":"0","summary":"药明合联(02268)于2026年4月8日发布公告指出，公司自2026年4月1日至4月8日期间，因多次行使其首次公开发售前购股权计划，共合计发行1,507,353股普通股，占公司此前已发行股本约0.12%。本次发行价格区间为每股1.8024港元至7.501港元。\n公告显示，本次变动使公司已发行股本由1,258,835,897股增至1,260,343,250股，库藏股数维持为0股。公司同时确认，前述股份发行已获董事会正式授权，并遵照所有适用的上市规则和相关法律法规进行。公告由执行董事、首席财务官兼公司秘书席晓捷签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://wuxixdc.com","stockEarnings":[{"period":"1week","weight":-0.0069},{"period":"1month","weight":-0.0121},{"period":"3month","weight":-0.018},{"period":"6month","weight":-0.1245},{"period":"1year","weight":0.4806},{"period":"ytd","weight":-0.0568}],"compareEarnings":[{"period":"1week","weight":-0.0126},{"period":"1month","weight":-0.023},{"period":"3month","weight":-0.0399},{"period":"6month","weight":-0.0205},{"period":"1year","weight":0.0832},{"period":"ytd","weight":-0.0118}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药明合联生物技术有限公司是一家主要从事提供提供抗体偶联药物（ADC）及其他生物偶联药物的全面合同研究、开发及制造组织（CRDMO）服务的投资控股公司。该公司的服务包括生物偶联药物、单克隆抗体中间体及生物偶联药物相关连接子及有效载荷的发现、工艺开发及优良生产质量管理规范（GMP）生产。该公司透过按有偿服务（FFS）基准的合约和按全时当量（FTE）基准的合约向客户提供CRDMO服务。该公司主要在国内市场、北美、欧洲和世界其他地区市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.222222,"avgChangeRate":0.010265},{"month":2,"riseRate":0.666667,"avgChangeRate":0.058284},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.010372},{"month":4,"riseRate":0.555556,"avgChangeRate":0.03555},{"month":5,"riseRate":0.333333,"avgChangeRate":0.006014},{"month":6,"riseRate":0.4,"avgChangeRate":-0.032735},{"month":7,"riseRate":0.4,"avgChangeRate":0.011785},{"month":8,"riseRate":0.4,"avgChangeRate":-0.114063},{"month":9,"riseRate":0.333333,"avgChangeRate":0.019767},{"month":10,"riseRate":0.777778,"avgChangeRate":0.151657},{"month":11,"riseRate":0.333333,"avgChangeRate":0.008796},{"month":12,"riseRate":0.111111,"avgChangeRate":-0.068876}],"exchange":"SEHK","name":"药明合联","nameEN":"WUXI XDC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明合联,02268,药明合联股票,药明合联股票老虎,药明合联股票老虎国际,药明合联行情,药明合联股票行情,药明合联股价,药明合联股市,药明合联股票价格,药明合联股票交易,药明合联股票购买,药明合联股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}